

Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes

Authors

Ángel Serna,¹ Víctor Navarro,¹ Gloria Iacoboni,¹ Laia López,² Juan-Manuel Sancho,² Eva González-Barca,³ Alberto López-García,⁴ Raúl Córdoba,⁴ Adolfo Sáez,⁵ Ana Jiménez-Ubieto,⁵ Ainara Ferrero,⁶ Tomás García,⁶ Ángela Sánchez,⁷ Cristina García,¹ Marc Bosch,¹ Alba Cabirta,¹ Moraima Jiménez,¹ Ana Marín-Niebla,¹ Francesc Bosch¹ and Pau Abrisqueta¹

¹Servei d'Hematologia, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona; ²Hematology Department, ICO-IJC-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona, Barcelona; ³Hematology Department, Institut Català d'Oncologia Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona; ⁴Fundacion Jimenez Diaz

University Hospital, Madrid; ⁵Servicio de Hematología, Hospital 12 de Octubre, Madrid; ⁶Hematology Department, University Hospital Arnau de Vilanova, Lleida and ⁷Hematology Department, Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Correspondence:

P. ABRISQUETA - pabrisqueta@vhio.net

<https://doi.org/10.3324/haematol.2024.285219>

Received: February 5, 2024.

Accepted: July 2, 2024.

Early view: July 11, 2024.

©2025 Ferrata Storti Foundation

Published under a CC BY-NC license 

SUPPLEMENTARY DATA

SUPPLEMENTAL TABLE AND FIGURE LEGENDS

Supplementary table 1. Unadjusted and adjusted for Inverse probability treatment weighting (IPTW) results for binary endpoints and survival univariate logistic and Cox models, respectively. Results of unadjusted are presented separately for Follicular Lymphoma (FL) and overall cohort (Mantle Cell Lymphoma (MCL) plus FL). HR represents Hazard Ratio for survival outcomes, while OR denotes Odds Ratio for binary outcomes, p-values indicate statistical significance.

Supplementary table 2. Hospitalization rates among patients diagnosed with SARS-CoV-2 infection in the bendamustine regimen plus rituximab maintenance (BR+RM) group versus RCHOP or RCVP regimen plus rituximab maintenance group (R-CHOP/R-CVP + RM).

Supplementary figure 1. Propensity score building according to an inverse probability treatment weighting (IPTW) ATE analysis. The analyzed variables are included in explanatory.

Supplementary Table 1

		Unadjusted				Adjusted	
		Only FL (n=178)		MCL/FL (n=214)		MCL/FL (n=207)	
		HR/OR (95% CI)	p-value	HR/OR (95% CI)	p-value	HR/OR (95% CI)	p-value
Survival	SARS-CoV2 Survival	0.05 (0.01 - 0.25)	<0.001	0.08 (0.02 - 0.31)	<0.001	0.11 (0.03 - 0.41)	0.001
Binary	Hospitalization	0.15 (0.04 - 0.52)	0.002	0.15 (0.05 - 0.43)	<0.001	0.17 (0.06 - 0.50)	0.001
	ICU admission	0.03 (0.00 - 0.18)	<0.001	0.06 (0.01 - 0.26)	<0.001	0.07 (0.02 - 0.28)	<0.001
	SARS-CoV2 infection	0.27 (0.08 - 0.83)	0.026	0.33 (0.12 - 0.85)	0.022	0.27 (0.09 - 0.69)	0.008
	SARS-CoV2 death	0.05 (0.00 - 0.24)	<0.001	0.06 (0.01 - 0.26)	<0.001	0.07 (0.02 - 0.28)	<0.001
	Seroconversion	0.56 (0.17 - 2.15)	0.353	0.48 (0.18 - 1.35)	0.142	0.55 (0.20 - 1.63)	0.251
	Vaccination	2.10 (0.30 - 8.94)	0.367	1.96 (0.43 - 6.67)	0.320	1.72 (0.32 - 6.25)	0.454

Supplementary Table 2

Year Sars-Cov2 infection	BR+RM		R-CHOP/R-CVP + RM	
	Hospitalization	No hospitalization	Hospitalization	No hospitalization
2020	1 (100%)	0 (0%)	5 (71%)	2 (29%)
2021	5 (100%)	0 (0%)	14 (58%)	10 (42%)
2022	3 (50%)	3 (50%)	7 (21%)	27 (79%)

Supplementary Figure 1

